These news items feature stories related to the Mayo Clinic Center for Individualized Medicine.
Mayo Clinic launches 50-gene cancer panel test
Mayo Clinic has launched CANCP, a new gene panel cancer test to help tailor chemotherapy to each patient based on the unique genomic signature of the patient's tumor. The test is available to Mayo patients and to providers worldwide through Mayo Medical Laboratories.
Got gas? It could mean you've got healthy gut microbes
Could passing gas, in some instances, be a sign that your gut microbes are busy keeping you healthy? Absolutely, says Purna C. Kashyap, MBBS, a Mayo Clinic gastroenterologist. "Eating foods that cause gas is the only way for the microbes in the gut to get nutrients," he says.
Mayo Clinic uncovers a crucial tumor suppression function of p53, the most commonly mutated gene in human cancers
Mayo Clinic researchers have uncovered a novel tumor suppressive role for p53, a gene that is mutated in more than half of all cancers found in humans. The researchers found that loss of p53 function caused overproduction of the kinase Aurora A, an enzyme involved in the process of cell division.
Mayo Clinic finds biomarker for Fuchs dystrophy, and more
Mayo Clinic ophthalmology researchers have found a likely indicator of Fuchs endothelial corneal dystrophy. Though researchers discovered no single genomic variant that caused Fuchs, they found that a repeated noncoding trinucleotide sequence correlated with the condition in patients 68 percent of the time.
Mayo Clinic shares lessons learned from genomics clinic for sequencing-based cancer care and diagnostics
About 1.5 years ago, Mayo Clinic opened the world's first integrated multidisciplinary genomics service, the Individualized Medicine Clinic, which uses genomics and next-generation sequencing technologies to personalize treatments for patients. Clinic leaders shared lessons learned in a special issue of the American Journal of Medical Genetics Part C.
Mayo Clinic develops faster tumor analysis software, speeds cancer discoveries
Mayo Clinic researchers have developed the Binary Indexing Mapping Algorithm, version 3 (BIMA V3), a freely available computer algorithm that identifies alterations in tumor genomes up to 20 times faster and with 25 percent greater accuracy than other popular genomic alignment programs.
Researchers use genomic sequencing to help identify new therapies for bile duct cancer
The Mayo Clinic Center for Individualized Medicine and the Translational Genomics Research Institute (TGen) have personalized drug treatments for patients with cholangiocarcinoma using genomic sequencing technologies. Clinically important findings suggest that targeting the epidermal growth factor receptor (EGFR) and the fibroblast growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease.
Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients
Mayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and shown that HER2 amplification is associated with particularly aggressive tumors. These findings suggest that administering trastuzumab to MPUC patients with HER2 amplification could improve outcomes, just as it has for breast cancer.
An ethical evolution at Mayo Clinic
Richard Sharp, Ph.D., director of the Bioethics Program in the Mayo Clinic Center for Individualized Medicine, talks about the program, its importance in the context of individualized medicine, and his recent transition from Cleveland Clinic to Mayo Clinic and Rochester, Minnesota.
Mayo Clinic studying genomics of antiplatelet heart medication
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) study, launched in summer 2013, examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina and cardiovascular death in patients who undergo percutaneous coronary intervention, commonly called angioplasty.
Using the human genome to customize medicine for patients
Journalist Mary Brophy Marcus takes an in-depth look at the Mayo Clinic Center for Individualized Medicine, highlighting the center's activities and vision as well as some patient success stories.
Cancer Genetics Inc. and Mayo Clinic announce initial next-generation sequencing projects for joint venture Oncospire
In May 2013, Cancer Genetics Inc. and Mayo Clinic formed Oncospire Genomics, a joint venture owned equally by both organizations. Oncospire announced in November 2013 that its initial projects would focus on developing next-generation sequencing panels for lung cancer, multiple myeloma and follicular lymphoma.
The push to personalize medicine
Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine, participated in the U.S. News Hospital of Tomorrow Forum about personalized medicine in November 2013. The primary value should be the needs of patients, he said, and "We can't live up to it unless we turn to genomics."
WuXi teams with Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine has licensed a panel of patient-derived xenograft models to WuXi, a China-based research and development company. WuXi now has a collection of patient-derived xenograft models from both Chinese and Western cancer patients that it is making available to the global cancer research community.
$5 million gift supports Mayo Clinic Center for Individualized Medicine in Florida
Cecilia and Dan Carmichael made a $5 million donation to Mayo Clinic to help expand the Center for Individualized Medicine in Jacksonville, Florida. The Carmichaels had previously donated $1 million to Mayo's breast cancer research efforts in Florida after Cecilia was diagnosed and treated for breast cancer at Mayo several years ago.